Molecular genetics in acute myeloid leukemia

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Acute myeloid leukemia (AML) is a complex blood cancer with diverse genetic subtypes.
• Molecular research has led to better characterization of AML, particularly in patients with normal karyotypes.

Purpose of the Study:

• To review the current state of molecular diagnostics in AML.
• To identify the most suitable diagnostic techniques for individual genetic markers.
• To discuss the clinical implications of molecular findings in AML.

Main Methods:

• Review of current literature on molecular diagnostics in AML.
• Analysis of established and emerging molecular markers (NPM1, FLT3, CEBPA, MLL-PTD, TET2, IDH1).
• Discussion of diagnostic techniques including quantitative real-time PCR and next-generation sequencing.

Main Results:

• A molecular data set including NPM1, FLT3, CEBPA mutations, and MLL-PTD aids in risk stratification and decisions regarding allogeneic stem cell transplantation.
• The number of relevant molecular markers is expanding with the discovery of mutations like TET2 and IDH1.
• Minimal residual disease monitoring is feasible for NPM1 and MLL-PTD mutated AML using quantitative real-time PCR.

Conclusions:

• Targeted therapies, such as FLT3 inhibitors, are being developed and tested for specific AML subgroups.
• Molecular techniques are increasingly translating into clinical practice for AML patient management.
• Personalized treatment strategies based on molecular profiles are becoming a reality in AML care.